Victor Levitsky

Chief Scientific Officer Circio

Deeply experienced tumor immunology scientist from international academic and industry roles, including John’s Hopkins, Roche and Molecular Partners

Dr Levitsky is a seasoned internationally recognized expert in immunology, oncology, T-cell immunotherapy and immuno-oncology with in-depth knowledge of preclinical, translational and early stage clinical drug development. He brings extensive experience in pre-clinical drug development of protein-based biologics and small molecules. Dr Levitsky is a medical doctor with a PhD in Virology and post-doctoral training in tumor biology at Karolinska Institute, Sweden. He spent the first 20 years of his career as an academic research scientist, including Associate Professor positions at the Karolinska Institute in Sweden and the Johns Hopkins University School of Medicine in the USA. Before joining Circio Dr Levitsky served as Tumor Immunology Leader and Senior Principal Scientist with Roche in Zurich, and his most recent position has been VP, Head of Oncology Research at Molecular Partners, Zurich, Switzerland and Head of Oncology Integration, Servier, Paris, France

Seminars

Thursday 29th January 2026
Harnessing Viral-Like Particles with Circular RNA to Boost Payload Expression Longevity
3:30 pm
  • Explore how viral-like particles (VLPs) enable efficient delivery of large circular RNA constructs for gene expression
  • Review preclinical data showing improved stability and expression outcomes compared to linear RNA formats
  • Understand the translational potential of VLP–circRNA systems for advancing nextgeneration gene editing therapies
victor levi Speaker at 5th mRNA Based Therapeutics Summit Europe